SAN FRANCISCO (GenomeWeb) – FitBiomics, a spinout from the Wyss Institute for Biologically Inspired Engineering at Harvard University, is sequencing the microbiomes of athletes to identify whether certain bacteria contribute to athletes' fitness. Its goal is to then isolate and develop those bacteria into probiotics.

Jonathan Scheiman, CEO of FitBiomics, is also a research fellow in George Church's lab at Harvard and the two are cofounders of the firm along with Alex Evans, who will serve as head of athletics. The firm currently has around 10 employees.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

Sponsored by

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.